Epstein–Barr virus–derived peptide presented on human leukocyte antigen molecule

EBV-derived peptides presented on HLA molecules refers to short fragments (typically 8–11 amino acids) processed from Epstein–Barr virus (EBV) proteins and displayed on the cell surface by human leukocyte antigen (HLA, the human MHC) molecules. These peptide–HLA complexes are recognized by immune effector cells—CD8+ cytotoxic T cells via HLA class I; CD4+ helper T cells via HLA class II; and NK cells via HLA-E presenting viral peptides. They are critical mediators of immune surveillance against EBV infection and its associated malignancies, enabling targeted destruction of virally infected or malignant cells. EBV manipulates the HLA antigen presentation machinery as an immune evasion strategy. These peptide–HLA complexes underpin the rationale for immunotherapies (including T cell and antibody therapies) and are studied as biomarkers of immune responses and disease states in infection, cancer, and some autoimmune diseases[1][2][3][4][5][6][7][8].

Other names

EBV–presented HLA peptideEBV antigenic peptide–HLA complexEpstein-Barr virus T cell epitopesEBV–peptide–MHC complex

Cytotoxic T cell activation (recognition and killing of infected or transformed cells displaying viral peptides on HLA class I); CD4+ T cell activation (helper T cell responses via HLA class II presentation); NK cell modulation (via HLA-E/peptide interactions influencing NKG2A/CD94 pathway, leading to activation or inhibition of NK cells); Immunoregulation (balance of effector and regulatory T cell responses, possibly linked to autoimmunity)